+3,393.8%
STRL vs GSK
+101.2%
+3,292.6%
-75.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.4% | -1.3% | +1.7% | +0.6% |
| 7D | -9.0% | -3.1% | -5.9% | -8.6% |
| 30D | -34.7% | -0.9% | -33.8% | -34.8% |
| 3M | -50.2% | -4.2% | -46.0% | -50.0% |
| 6M | -64.1% | -1.6% | -62.6% | -64.5% |
| YTD | -9.8% | +2.6% | -12.4% | -12.0% |
| 1Y | -17.2% | +6.2% | -23.4% | -20.0% |
| 3Y | +317.5% | +55.0% | +262.5% | +240.8% |
| 5Y | +856.3% | +42.8% | +813.4% | +688.5% |
| 10Y | +3,393.8% | +102.1% | +3,291.7% | +2,556.7% |
| All | +3,393.8% | +101.2% | +3,292.6% | +2,556.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling